BR112013006861A2 - ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada - Google Patents

ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada

Info

Publication number
BR112013006861A2
BR112013006861A2 BR112013006861A BR112013006861A BR112013006861A2 BR 112013006861 A2 BR112013006861 A2 BR 112013006861A2 BR 112013006861 A BR112013006861 A BR 112013006861A BR 112013006861 A BR112013006861 A BR 112013006861A BR 112013006861 A2 BR112013006861 A2 BR 112013006861A2
Authority
BR
Brazil
Prior art keywords
release system
binder
controlled release
compound
preparing
Prior art date
Application number
BR112013006861A
Other languages
English (en)
Inventor
Franciscus Van Nostrum Cornelis
Johanna Ferdinand Rijcken Cristianne
Altintas Isil
Anna Wilhelmus Kruijtzer Johannes
Matthias Joseph Liskamp Robertus
Van Der Wal Steffen
Everhardus Hennink Wilhelmus
Original Assignee
Cristal Delivery B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristal Delivery B V filed Critical Cristal Delivery B V
Publication of BR112013006861A2 publication Critical patent/BR112013006861A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada a presente invenção refere-se a uma classe específica de ligantes biodegradáveis, garantindo conjugação transitoriamente estável de blocos de construção e/ou de compostos bioativos em sistemas de liberação de fármaco ( dds) , tais como dds baseados em micelas ou hidrogéis poliméricos. além disso, a presente invenção refere-se a compostos, compreendendo ditos ligantes , e especialmente ditos ligantes biodegradáveis, em um sistema de liberação de fármaco. além disso, a invenção refere-se a um sistema de liberação controlada compreendendo uma matriz polimérica, capaz de liberar um ingrediente ativo, sendo que o ingrediente ativo é covalentemente ligado às moléculas de polímero da matriz polimérica através de di tos ligantes, bem como a um método para sintetizar esses ligantes e preparar tais sistemas de liberação controlada.
BR112013006861A 2010-09-21 2011-07-14 ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada BR112013006861A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38473010P 2010-09-21 2010-09-21
PCT/NL2011/050509 WO2012039602A1 (en) 2010-09-21 2011-07-14 Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith

Publications (1)

Publication Number Publication Date
BR112013006861A2 true BR112013006861A2 (pt) 2019-07-02

Family

ID=44630016

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013006861A BR112013006861A2 (pt) 2010-09-21 2011-07-14 ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada

Country Status (9)

Country Link
US (1) US9339554B2 (pt)
EP (1) EP2618845B1 (pt)
JP (2) JP5934221B2 (pt)
KR (1) KR101961961B1 (pt)
CN (1) CN103209710B (pt)
BR (1) BR112013006861A2 (pt)
CA (1) CA2811869A1 (pt)
ES (1) ES2776983T3 (pt)
WO (1) WO2012039602A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2389960B1 (en) 2006-06-15 2018-02-28 MicroVention, Inc. Environmentally responsive hydrogel
US8470035B2 (en) 2007-12-21 2013-06-25 Microvention, Inc. Hydrogel filaments for biomedical uses
US10639396B2 (en) 2015-06-11 2020-05-05 Microvention, Inc. Polymers
US9456823B2 (en) 2011-04-18 2016-10-04 Terumo Corporation Embolic devices
EP2723388B1 (en) 2011-06-27 2021-04-14 Cristal Delivery B.V. Controlled release system
WO2014142653A1 (en) 2013-03-11 2014-09-18 Cristal Delivery B.V. Vaccination composition
CN110433326A (zh) * 2014-04-29 2019-11-12 微仙美国有限公司 包含活性剂的聚合物
JP2017537298A (ja) 2014-10-03 2017-12-14 サンウェル・エンジニアリング・カンパニー・リミテッド 略一定の温度を維持するための熱シールド
JP7029957B2 (ja) 2014-10-03 2022-03-04 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド インタクトな細菌由来のベシクルへの低分子化合物の充填の向上
SG10201913945QA (en) 2015-06-04 2020-03-30 Crititech Inc Taxane particles and their use
EP3377047A1 (en) 2015-11-20 2018-09-26 Cristal Delivery B.V. Nanoparticles with active targeting
JP6970683B2 (ja) 2016-04-04 2021-11-24 クリティテック・インコーポレイテッド 固形腫瘍治療のための方法
WO2018172546A1 (en) 2017-03-24 2018-09-27 Rigontec Gmbh Method for designing rig-i ligands
WO2018227037A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
US10398646B2 (en) 2017-06-14 2019-09-03 Crititech, Inc. Methods for treating lung disorders
BR112020005814A2 (pt) 2017-10-03 2020-09-24 Crititech, Inc. administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer
CN111615405B (zh) * 2017-11-17 2023-11-28 国家科学研究中心 聚合物前药及其皮下和/或肌内给药
KR20210032422A (ko) 2018-07-13 2021-03-24 크리스탈 딜리버리 비.브이. 티오사이클로헵틴 유도체들 및 이들의 용도
EP3990635A1 (en) 2019-06-27 2022-05-04 Rigontec GmbH Design method for optimized rig-i ligands

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2496275A (en) * 1945-08-17 1950-02-07 Eastman Kodak Co Polymers and copolymers of unsaturated amides
US3220986A (en) * 1960-12-27 1965-11-30 Union Carbide Corp 2-vinyloxyethyl sulfide compounds and polymerization products thereof
GR64493B (en) * 1976-07-06 1980-03-31 Huels Chemische Werke Ag Method for the preparation of methalylo-sulfonic natrium
IT1174496B (it) * 1984-02-17 1987-07-01 Nuovo Consor Sanitar Nazionale Composti ad attivita'ipolipemizzante
FR2687400A1 (fr) * 1992-02-17 1993-08-20 Atochem Elf Sa Nouveaux composes (meth)acryliques, leur procede de preparation et leur application a la synthese de nouveaux polymeres.
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
BR9807030B1 (pt) * 1997-01-28 2009-01-13 agente tensoativo polimerizÁvel, e, soluÇço aquosa de tensoativo.
EP1072617A1 (en) 1999-07-30 2001-01-31 Universiteit van Utrecht Temperature sensitive polymers
US7425581B2 (en) 1999-07-30 2008-09-16 Universiteit Utrecht Temperature sensitive polymers
KR20080030564A (ko) * 2005-05-12 2008-04-04 태피스트리 파마슈티컬스 인코퍼레이티드 표적 컨쥬게이트에 적합한 분자 구조물
JP5622117B2 (ja) * 2008-07-21 2014-11-12 ポリテリクスリミテッド 生体分子を接合するための新規な試薬及び方法
BRPI0913704A2 (pt) 2008-09-18 2017-06-20 Univ Utrecht Holding Bv método para a preparação de um sistema de liberação controlada

Also Published As

Publication number Publication date
KR20130136991A (ko) 2013-12-13
KR101961961B1 (ko) 2019-03-25
WO2012039602A1 (en) 2012-03-29
CA2811869A1 (en) 2012-03-29
US20130261094A1 (en) 2013-10-03
JP5934221B2 (ja) 2016-06-15
CN103209710A (zh) 2013-07-17
EP2618845A1 (en) 2013-07-31
JP2016145250A (ja) 2016-08-12
EP2618845B1 (en) 2020-02-26
JP2013537224A (ja) 2013-09-30
US9339554B2 (en) 2016-05-17
CN103209710B (zh) 2016-04-06
JP6144383B2 (ja) 2017-06-07
ES2776983T3 (es) 2020-08-03

Similar Documents

Publication Publication Date Title
BR112013006861A2 (pt) ligante para ser utilizado em um sistema de liberação de fármaco, composto compreendendo um ligante, uso de um composto, sistema de liberação controlada e método para preparar um sistema de liberação controlada
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
ECSP11011183A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
CR11801A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
UY33485A (es) Derivados de acido(2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos.
CO6640285A2 (es) 5-alquinil-pirimidinas
ECSP10010695A (es) Compuestos de piridina
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
RS53890B1 (en) STABILIZED POLYMER DELIVERY SYSTEM
UY30824A1 (es) Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones.
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
BR112013006341A2 (pt) formulações agrícolas líquidas com estabilidade aperfeiçoada
CR9786A (es) Compuestos de bencimidazol-tiofeno
BR112012029647A2 (pt) novos derivados de pirimidinas
BR112014018617A8 (pt) Polímero catiônico com base em glicogênio,complexo entre um polímero catiônico com base em glicogênio e um composto aniônico, composição farmacêutica, e, uso de um complexo
BR112013016770A2 (pt) formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica
UY31645A1 (es) Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso.
ECSP11010786A (es) 5-alquinil-pirimidinas
BR112017013260A2 (pt) composição de catalisador para a cura de resinas contendo grupos de epóxi
BR112015024971A2 (pt) derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk
CL2010001432A1 (es) Compuestos derivados de 2-oxo-alquil-1-piperazin-2-ona, afines por los receptores p75ntr; procedimiento para preparar los compuestos; compuesto intermediario; medicamento y composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2628 DE 18-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]